Melane Sampson, Author at BioTuesdays

Developments

Larimar reports positive data from study of nomlabofusp in FA

Larimar Therapeutics (NASDAQ: LRMR) has announced positive 25 mg and 50 mg data from the ongoing long-term open label (OL) study evaluating daily subcutaneous injections of nomlabofusp self-administered or administered...

September 30, 2025

Executive Moves

Dr. Usman Azam appointed president and CEO of Cue

Cue Biopharma (NASDAQ: CUE) has announced that Usman Azam, MD has been appointed president and CEO of Cue Biopharma, effective today. Daniel Passeri will transition from his current role as CEO to one of strategic...

September 30, 2025

Feature

Cell One Partners guiding cell and gene therapy from breakthrough science to market impact

Consultancy Cell One Partners is helping innovators translate scientific ambition into viable commercial solutions as the cell and gene therapy industry pushes toward its next era of breakthroughs. Through deep domain...

September 30, 2025

Developments

Anebulo announces first dose in SAD study of IV selonabant for ACI

Anebulo Pharmaceuticals (NASDAQ: ANEB) has announced first patients dosed in its Phase 1 single ascending dose (SAD) study intravenous selonabant—under development for acute cannabis-induced (ACI) toxicity—in healthy...

September 26, 2025

Developments

USPTO grants Nexalin patent for next-gen HALO Clarity device

Nexalin Technology (NASDAQ: NXL; NXLIW) has announced that the United States Patent and Trademark Office (USPTO) has issued a design patent providing 15 years of protection for the company’s next-generation HALO Clarity...

September 25, 2025

Developments

CIPO grants NOA to Moleculin for patent covering Annamycin

Moleculin Biotech (NASDAQ: MBRX) announced that the Canadian Intellectual Property Office (CIPO) has issued a notice of allowance (NOA) for a patent covering methods of making a preliposomal Annamycin lyophilizate with...

September 25, 2025

Developments

TGA approves MediWound’s NexoBrid for burn management in Australia

MediWound (NASDAQ: MDWD) has announced that Australia’s Therapeutic Goods Administration (TGA) has granted marketing authorization for NexoBrid—an enzymatic therapy for the removal of eschar in both adult and pediatric...

September 25, 2025

Developments

GeoVax expands with additional solid tumor targets for Gedeptin

GeoVax Labs (NASDAQ: GOVX) has announced the expansion of its oncology development strategy to evaluate additional solid tumor targets for Gedeptin—its gene-directed enzyme prodrug therapy. According to GeoVax, the...

September 24, 2025

Developments

Hemogenyx, Cellin sign LOI to commercialize cell therapy for R/R AML in Estonia

Hemogenyx Pharmaceuticals (LSE: HEMO) has announced the signing of a letter of intent (LOI) with closely held Cellin Technologies to explore the commercialization of its HG-CT-1 CAR-T cell therapy for the treatment of...

September 23, 2025

Executive Moves

Onco appoints Dr. Michael Lock to scientific and clinical advisory board

Onco-Innovations (CBOE CA: ONCO; Frankfurt: W1H, WKN: A3EKSZ; OTCQB: ONNVF) has announced the appointment of staff radiation oncologist, Dr. Michael Lock, to its scientific and clinical advisory board. Dr. Lock is a...

September 23, 2025

Author - Melane Sampson

Larimar reports positive data from study of nomlabofusp in FA

Dr. Usman Azam appointed president and CEO of Cue

Cell One Partners guiding cell and gene therapy from breakthrough science to market impact

Anebulo announces first dose in SAD study of IV selonabant for ACI

USPTO grants Nexalin patent for next-gen HALO Clarity device

CIPO grants NOA to Moleculin for patent covering Annamycin

TGA approves MediWound’s NexoBrid for burn management in Australia

GeoVax expands with additional solid tumor targets for Gedeptin

Hemogenyx, Cellin sign LOI to commercialize cell therapy for R/R AML in Estonia

Onco appoints Dr. Michael Lock to scientific and clinical advisory board

Subscribe